Dr. Brett J. Smith, M.D.
Preventive Medicine & Public Health (Public Health & General Preventive Medicine Physician)
At a glance
- In the NPI registry since
- 2012
Licensed in California since 2012, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Public Health & General Preventive Medicine Physician primary
CA license A123185 (first issued 2012; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Preventive Medicine & Public Health per capita by county →
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $4,241,407 in research payments for these studies, mostly to the institutions running them.
- LP352-106: DDI study with Carbamazepine
H. Lundbeck A S - A phase 1, randomized, placebo-controlled, double-blind, parallel-grou
GlaxoSmithKline, LLC. - A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
AbbVie Inc. · Completed · NCT06946524 - A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants
Eli Lilly and Company · Completed · NCT06311656 - A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Administration with Prefilled Pen Relative to Prefilled Syringe
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.